CNBX Pharmaceuticals Inc. SEC filings CNBX
CNBX Pharmaceuticals Inc. has 301 filings in SEC EDGAR's recent list, going back to Jan 9, 2006. Its latest annual report, Form 10-K, was filed on Dec 1, 2025 for the period ended Aug 31, 2025. The latest quarterly report (Form 10-Q) was filed on Jun 24, 2026, covering the quarter ended May 31, 2026. The most recent current report (Form 8-K) was filed on Oct 1, 2026 (auditor change). The company's fiscal year ends on August 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Auditor change
|
Oct 1, 2026 | Sep 28, 2026 |
| 8-K |
Current report
Material agreement
|
Mar 17, 2026 | Mar 10, 2026 |
| 8-K |
Current report
Material agreement
|
Jan 30, 2025 | Jan 24, 2025 |
| 8-K |
Current report
Auditor change
|
Mar 22, 2024 | Mar 18, 2024 |
| 8-K |
Current report
Officer or director change
|
Feb 8, 2023 | Jan 31, 2023 |
| 8-K |
Current report
Officer or director change
|
Dec 29, 2022 | Dec 25, 2022 |
| 8-K |
Current report
Officer or director change
|
Jul 25, 2022 | Jul 20, 2022 |
| 8-K |
Current report
Bylaw or fiscal year change
|
May 13, 2022 | May 10, 2022 |
| 8-K |
Current report
Bylaw or fiscal year change, Other events
|
Mar 28, 2022 | Mar 28, 2022 |
| 8-K |
Current report
Material agreement, New debt
|
Mar 16, 2022 | Mar 11, 2022 |
| 8-K |
Current report
Material agreement
|
Feb 17, 2022 | Feb 15, 2022 |
| 8-K |
Current report
Officer or director change
|
Nov 19, 2021 | Nov 16, 2021 |
| 8-K |
Current report
Officer or director change
|
Sep 13, 2021 | Sep 3, 2021 |
| 8-K |
Current report
Officer or director change
|
Jul 19, 2021 | Jul 15, 2021 |
| 8-K |
Current report
Officer or director change
|
Jul 6, 2021 | Jul 1, 2021 |
| 8-K |
Current report
Material agreement
|
Apr 28, 2021 | Apr 23, 2021 |
| 8-K |
Current report
Material agreement
|
Dec 21, 2020 | Dec 16, 2020 |
| 8-K |
Current report
Regulation FD disclosure
|
Nov 16, 2020 | Nov 16, 2020 |
| 8-K |
Current report
Officer or director change
|
Sep 2, 2020 | Sep 2, 2020 |
| 8-K |
Current report
Regulation FD disclosure
|
Apr 17, 2020 | Apr 16, 2020 |
| 8-K |
Current report
Officer or director change
|
Apr 17, 2020 | Apr 16, 2020 |
| 8-K |
Current report
Change in control
|
Nov 8, 2019 | Nov 6, 2019 |
| 8-K |
Current report
Auditor change
|
Nov 7, 2019 | Nov 6, 2019 |
| 8-K |
Current report
Officer or director change
|
Oct 11, 2019 | Oct 7, 2019 |
| 8-K |
Current report
Officer or director change
|
Oct 7, 2019 | Oct 7, 2019 |
| 8-K |
Current report
Officer or director change
|
Oct 3, 2019 | Oct 2, 2019 |
| 8-K |
Current report
Auditor change
|
Jul 23, 2019 | Jul 21, 2019 |
| 8-K |
Current report
Officer or director change
|
Jun 25, 2019 | Jun 21, 2019 |
| 8-K |
Current report
Material agreement, Unregistered share sale
|
Feb 13, 2019 | Feb 7, 2019 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Other events
|
Sep 27, 2018 | Sep 24, 2018 |
| 8-K |
Current report
Material agreement
|
Aug 14, 2018 | Aug 10, 2018 |
| 8-K |
Current report
Material agreement
|
May 2, 2018 | Apr 30, 2018 |
| 8-K |
Current report
Officer or director change
|
Feb 14, 2018 | Feb 1, 2018 |
| 8-K |
Current report
Officer or director change
|
Jan 30, 2018 | Jan 29, 2018 |
| 8-K |
Current report
Material agreement
|
Dec 19, 2017 | Dec 14, 2017 |
| 8-K |
Current report
Auditor change
|
Nov 13, 2017 | Nov 13, 2017 |
| 8-K |
Current report
Officer or director change
|
Nov 13, 2017 | Nov 12, 2017 |
| 8-K |
Current report
Material agreement
|
May 10, 2017 | May 8, 2017 |
| 8-K |
Current report
Officer or director change
|
Dec 13, 2016 | Dec 9, 2016 |
| 8-K |
Current report
Auditor change
|
Mar 22, 2016 | Mar 17, 2016 |
| 8-K |
Current report
Material agreement
|
Feb 22, 2016 | Feb 22, 2016 |
| 8-K |
Current report
Material agreement, Officer or director change
|
Jan 29, 2016 | Jan 25, 2016 |
| 8-K |
Current report
Restatement
|
Oct 13, 2015 | Oct 12, 2015 |
| 8-K |
Current report
Material agreement
|
Oct 8, 2015 | Oct 7, 2015 |
| 8-K |
Current report
Regulation FD disclosure
|
May 28, 2015 | May 27, 2015 |
| 8-K |
Current report
Officer or director change
|
Apr 9, 2015 | Apr 6, 2015 |
| 8-K |
Current report
Material agreement
|
Feb 17, 2015 | Feb 15, 2015 |
| 8-K |
Current report
Material agreement
|
Feb 3, 2015 | Jan 29, 2015 |
| 8-K |
Current report
Officer or director change
|
Jan 23, 2015 | Jan 23, 2015 |
| 8-K |
Current report
Material agreement
|
Jan 6, 2015 | Dec 31, 2014 |
| 8-K |
Current report
Other events
|
Dec 16, 2014 | Dec 11, 2014 |
| 8-K |
Current report
Material agreement
|
Nov 5, 2014 | Nov 4, 2014 |
| 8-K |
Current report
Regulation FD disclosure
|
Aug 1, 2014 | Jul 31, 2014 |
| 8-K |
Current report
Material agreement
|
Jul 25, 2014 | Jul 24, 2014 |
| 8-K |
Current report
Bylaw or fiscal year change
|
Jun 20, 2014 | Jun 20, 2014 |
| 8-K |
Current report
Change in control, Officer or director change
|
Apr 30, 2014 | Apr 25, 2014 |
| 8-K |
Current report
Acquisition or sale of assets
|
Apr 8, 2014 | Apr 4, 2014 |
| 8-K |
Current report
Bylaw or fiscal year change
|
Dec 9, 2013 | Dec 4, 2013 |
| 8-K |
Current report
Material agreement, Agreement ended, Unregistered share sale
|
Nov 25, 2013 | Nov 20, 2013 |
| 8-K |
Current report
Material agreement
|
Oct 29, 2013 | Oct 24, 2013 |
| 8-K |
Current report
Regulation FD disclosure
|
Oct 22, 2013 | Oct 21, 2013 |
| 8-K |
Current report
Material agreement, Unregistered share sale
|
Jul 2, 2013 | Jun 28, 2013 |
| 8-K |
Current report
Unregistered share sale
|
Jun 28, 2013 | Jun 24, 2013 |
| 8-K |
Current report
Officer or director change
|
Aug 28, 2012 | Aug 27, 2012 |
| 8-K |
Current report
Officer or director change
|
Jul 27, 2012 | Jul 25, 2012 |
| 8-K |
Current report
Officer or director change
|
Apr 17, 2012 | Apr 14, 2012 |
| 8-K/A |
Amended current report
Auditor change
|
Nov 17, 2011 | Nov 8, 2011 |
| 8-K |
Current report
Material agreement, Agreement ended, Acquisition or sale of assets, Change in control
|
Nov 14, 2011 | Nov 8, 2011 |
| 8-K |
Current report
Auditor change
|
Nov 14, 2011 | Nov 8, 2011 |
| 8-K |
Current report
Agreement ended, Officer or director change
|
Nov 7, 2011 | Nov 2, 2011 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Jul 5, 2011 | Jul 1, 2011 |
| 8-K |
Current report
Auditor change
|
Jun 29, 2011 | Jun 27, 2011 |
| 8-K |
Current report
Material agreement, New debt, Unregistered share sale
|
Jun 20, 2011 | Jun 17, 2011 |
| 8-K |
Current report
Material agreement, Acquisition or sale of assets, Unregistered share sale, Change in control, Officer or director change
|
Jun 7, 2011 | May 31, 2011 |
| 8-K |
Current report
Change to shareholder rights, Bylaw or fiscal year change
|
May 13, 2011 | May 10, 2011 |
| 8-K |
Current report
Bylaw or fiscal year change, Other events
|
May 10, 2011 | May 5, 2011 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Bylaw or fiscal year change
|
Apr 22, 2011 | Apr 18, 2011 |
| 8-K |
Current report
Bylaw or fiscal year change
|
Sep 30, 2010 | Sep 30, 2010 |
| 8-K |
Current report
Acquisition or sale of assets, Regulation FD disclosure
|
Dec 1, 2009 | Nov 25, 2009 |
| 8-K/A |
Amended current report
Material agreement
|
Jul 7, 2009 | Jun 30, 2009 |
| 8-K |
Current report
Material agreement
|
May 27, 2009 | May 22, 2009 |
| 8-K |
Current report
Officer or director change
|
Aug 28, 2007 | Aug 27, 2007 |
Showing 82 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- CNBX (OTC)
- Fiscal year ends
- August 31
- Incorporated in
- NV
- Headquarters
- Bethesda, MD
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1343009
- Former names
- Cannabics Pharmaceuticals Inc. (until Mar 16, 2022); American Mining Corp (until May 1, 2014); Thrust Energy Corp. (until May 10, 2011)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.